Keep Us Strong WikiLeaks logo

Currently released so far... 97115 / 251,287

Articles

Browse latest releases

Browse by creation date

Browse by origin

A B C D F G H I J K L M N O P Q R S T U V W Y Z

Browse by tag

A B C D E F G H I J K L M N O P Q R S T U V W X Y Z
ETRD EAGR ETTC EAID ECON EFIN ECIN EINV ELAB EAIR ENRG EPET EWWT ECPS EIND EMIN ELTN EC ETMIN EUC EZ ET ELECTIONS ENVR EU EUN EG EINT ER ECONOMICS ES EMS ENIV EEB EN ECE ECOSOC EK ENVIRONMENT EFIS EI EWT ENGRD ECPSN EXIM EIAD ERIN ECPC EDEV ENGY ECTRD EPA ESTH ECCT EINVECON ENGR ERTD EUR EAP EWWC ELTD EL EXIMOPIC EXTERNAL ETRDEC ESCAP ECO EGAD ELNT ECONOMIC ENV ETRN EIAR EUMEM ENRGPARMOTRASENVKGHGPGOVECONTSPLEAID EREL ECOM ECONETRDEAGRJA ETCC ETRG ECONOMY EMED ETR ENERG EITC EFINOECD EURM EENG ERA EXPORT ENRD ECONEINVETRDEFINELABETRDKTDBPGOVOPIC EGEN EBRD EVIN ETRAD ECOWAS EFTA ECONETRDBESPAR EGOVSY EPIN EID ECONENRG EDRC ESENV ETT EB ENER ELTNSNAR ECHEVARRIA ETRC EPIT EDUC ESA EFI ENRGY ESCI EE EAIDXMXAXBXFFR EETC ECIP EIAID EIVN EBEXP ESTN EING EGOV ETRA EPETEIND ELAN ETRDGK EAIDRW ETRDEINVECINPGOVCS EPEC ENVI ELN EAG EPCS EPRT EPTED ETRB EUM EAIDS EFIC EFINECONEAIDUNGAGM EAIDAR ESF EIDN ELAM EDU EV EAIDAF ECN EDA EXBS EINTECPS ENRGTRGYETRDBEXPBTIOSZ EPREL EAC EINVEFIN ETA EAGER EINDIR ECA ECLAC ELAP EITI EUCOM ECONEFINETRDPGOVEAGRPTERKTFNKCRMEAID EARG ELDIN EINVKSCA ENNP EFINECONCS EFINTS ECCP ETC EAIRASECCASCID EINN ETRP EAIDNI EFQ ECOQKPKO EGPHUM EBUD ECONEINVEFINPGOVIZ ENERGY ELB EINDETRD EMI ECONEFIN EIB EURN ETRDEINVTINTCS EIN EFIM ETIO ELAINE EMN EATO EWTR EIPR EINVETC ETTD ETDR EIQ ECONCS EPPD ENRGIZ EISL ESPINOSA ELEC EAIG ESLCO EUREM ENTG ERD EINVECONSENVCSJA EEPET EUNCH ECINECONCS ETRO ETRDECONWTOCS ECUN EFND EPECO EAIRECONRP ERGR ETRDPGOV ECPN ENRGMO EPWR EET EAIS EAGRE EDUARDO EAGRRP EAIDPHUMPRELUG EICN ECONQH EVN EGHG ELBR EINF EAIDHO EENV ETEX ERNG ED
KMDR KPAO KPKO KJUS KCRM KGHG KFRD KWMN KDEM KTFN KHIV KGIC KIDE KSCA KNNP KHUM KIPR KSUM KISL KIRF KCOR KRCM KPAL KWBG KN KS KOMC KSEP KFLU KPWR KTIA KSEO KMPI KHLS KICC KSTH KMCA KVPR KPRM KE KU KZ KFLO KSAF KTIP KTEX KBCT KOCI KOLY KOR KAWC KACT KUNR KTDB KSTC KLIG KSKN KNN KCFE KCIP KGHA KHDP KPOW KUNC KDRL KV KPREL KCRS KPOL KRVC KRIM KGIT KWIR KT KIRC KOMO KRFD KUWAIT KG KFIN KSCI KTFIN KFTN KGOV KPRV KSAC KGIV KCRIM KPIR KSOC KBIO KW KGLB KMWN KPO KFSC KSEAO KSTCPL KSI KPRP KREC KFPC KUNH KCSA KMRS KNDP KR KICCPUR KPPAO KCSY KTBT KCIS KNEP KFRDCVISCMGTCASCKOCIASECPHUMSMIGEG KNNB KGCC KINR KPOP KMFO KENV KNAR KVIR KDRG KDMR KFCE KNAO KDEN KGCN KICA KIMMITT KMCC KLFU KMSG KSEC KUM KCUL KMNP KSMT KCOM KOMCSG KSPR KPMI KRAD KIND KCRP KAUST KWAWC KTER KCHG KRDP KPAS KITA KTSC KPAOPREL KWGB KIRP KJUST KMIG KLAB KTFR KSEI KSTT KAPO KSTS KLSO KWNN KPOA KHSA KNPP KPAONZ KBTS KWWW KY KJRE KPAOKMDRKE KCRCM KSCS KWMNCI KESO KWUN KPLS KIIP KEDEM KPAOY KRIF KGICKS KREF KTRD KFRDSOCIRO KTAO KJU KWMNPHUMPRELKPAOZW KEN KO KNEI KEMR KKIV KEAI KWAC KRCIM KWCI KFIU KWIC KCORR KOMS KNNO KPAI KBWG KTTB KTBD KTIALG KILS KFEM KTDM KESS KNUC KPA KOMCCO KCEM KRCS KWBGSY KNPPIS KNNPMNUC KWN KERG KLTN KALM KCCP KSUMPHUM KREL KGH KLIP KTLA KAWK KWMM KVRP KVRC KAID KSLG KDEMK KX KIF KNPR KCFC KFTFN KTFM KPDD KCERS KMOC KDEMAF KMEPI KEMS KDRM KEPREL KBTR KEDU KNP KIRL KNNR KMPT KISLPINR KTPN KA KJUSTH KPIN KDEV KTDD KAKA KFRP KWNM KTSD KINL KJUSKUNR KWWMN KECF KWBC KPRO KVBL KOM KFRDKIRFCVISCMGTKOCIASECPHUMSMIGEG KEDM KFLD KLPM KRGY KNNF KICR KIFR KM KWMNCS KAWS KLAP KPAK KDDG KCGC KID KNSD KMPF KPFO KDP KCMR KRMS KNPT KNNNP KTIAPARM KDTB KNUP KPGOV KNAP KNNC KUK KSRE KREISLER KIVP KQ KTIAEUN KPALAOIS KRM KISLAO KWM KFLOA
PHUM PINR PTER PGOV PREL PREF PL PM PHSA PE PARM PINS PK PUNE PO PALESTINIAN PU PBTS PROP PTBS POL POLI PA PGOVZI POLMIL POLITICAL PARTIES POLM PD POLITICS POLICY PAS PMIL PINT PNAT PV PKO PPOL PERSONS PING PBIO PH PETR PARMS PRES PCON PETERS PRELBR PT PLAB PP PAK PDEM PKPA PSOCI PF PLO PTERM PJUS PSOE PELOSI PROPERTY PGOVPREL PARP PRL PNIR PHUMKPAL PG PREZ PGIC PBOV PAO PKK PROV PHSAK PHUMPREL PROTECTION PGOVBL PSI PRELPK PGOVENRG PUM PRELKPKO PATTY PSOC PRIVATIZATION PRELSP PGOVEAIDUKNOSWGMHUCANLLHFRSPITNZ PMIG PREC PAIGH PROG PSHA PARK PETER POG PHUS PPREL PS PTERPREL PRELPGOV POV PKPO PGOVECON POUS PGOVPRELPHUMPREFSMIGELABEAIDKCRMKWMN PWBG PMAR PREM PAR PNR PRELPGOVEAIDECONEINVBEXPSCULOIIPBTIO PARMIR PGOVGM PHUH PARTM PN PRE PTE PY POLUN PPEL PDOV PGOVSOCI PIRF PGOVPM PBST PRELEVU PGOR PBTSRU PRM PRELKPAOIZ PGVO PERL PGOC PAGR PMIN PHUMR PVIP PPD PGV PRAM PINL PKPAL PTERE PGOF PINO PHAS PODC PRHUM PHUMA PREO PPA PEPFAR PGO PRGOV PAC PRESL PORG PKFK PEPR PRELP PREFA PNG PGOVPHUMKPAO PRELECON PINOCHET PFOR PGOVLO PHUMBA PRELC PREK PHUME PHJM POLINT PGOVPZ PGOVKCRM PGOVE PHALANAGE PARTY PECON PEACE PROCESS PLN PRELSW PAHO PEDRO PRELA PASS PPAO PGPV PNUM PCUL PGGV PSA PGOVSMIGKCRMKWMNPHUMCVISKFRDCA PGIV PRFE POGOV PEL PBT PAMQ PINF PSEPC POSTS PHUMPGOV PVOV PHSAPREL PROLIFERATION PENA PRELTBIOBA PIN PRELL PGOVPTER PHAM PHYTRP PTEL PTERPGOV PHARM PROTESTS PRELAF PKBL PRELKPAO PKNP PARMP PHUML PFOV PERM PUOS PRELGOV PHUMPTER PARAGRAPH PERURENA PBTSEWWT PCI PETROL PINSO PINSCE PQL PEREZ PBS

Browse by classification

Community resources

courage is contagious

Viewing cable 06WELLINGTON475, INDUSTRY SEES HIGHER COSTS UNDER NEW ZEALAND-AUSTRALIA

If you are new to these pages, please read an introduction on the structure of a cable as well as how to discuss them with others. See also the FAQs

Understanding cables
Every cable message consists of three parts:
  • The top box shows each cables unique reference number, when and by whom it originally was sent, and what its initial classification was.
  • The middle box contains the header information that is associated with the cable. It includes information about the receiver(s) as well as a general subject.
  • The bottom box presents the body of the cable. The opening can contain a more specific subject, references to other cables (browse by origin to find them) or additional comment. This is followed by the main contents of the cable: a summary, a collection of specific topics and a comment section.
To understand the justification used for the classification of each cable, please use this WikiSource article as reference.

Discussing cables
If you find meaningful or important information in a cable, please link directly to its unique reference number. Linking to a specific paragraph in the body of a cable is also possible by copying the appropriate link (to be found at theparagraph symbol). Please mark messages for social networking services like Twitter with the hash tags #cablegate and a hash containing the reference ID e.g. #06WELLINGTON475.
Reference ID Created Released Classification Origin
06WELLINGTON475 2006-06-21 23:14 2011-04-28 00:00 UNCLASSIFIED//FOR OFFICIAL USE ONLY Embassy Wellington
VZCZCXRO6701
RR RUEHNZ
DE RUEHWL #0475/01 1722314
ZNR UUUUU ZZH
R 212314Z JUN 06
FM AMEMBASSY WELLINGTON
TO RUEHC/SECSTATE WASHDC 2921
INFO RUCPDOC/USDOC WASHDC 0062
RUEHNZ/AMCONSUL AUCKLAND 0791
RUEHBY/AMEMBASSY CANBERRA 4458
RUEHDN/AMCONSUL SYDNEY 0448
UNCLAS SECTION 01 OF 02 WELLINGTON 000475 
 
SIPDIS 
 
SENSITIVE 
SIPDIS 
 
STATE PASS USTR-JJENSEN 
STATE PASS FDA FOR OFFICE OF INTERNATIONAL PROGRAMS 
STATE FOR EAP/ANP-DRICCI AND EB/TPP/BTA/ANA-MBGOODMAN 
COMMERCE FOR ABENAISSA/4530/ITA/MAC/AP/OSAO 
SYDNEY FOR CS 
 
E.O. 12958: N/A 
TAGS: ETRD ECON NZ
SUBJECT: INDUSTRY SEES HIGHER COSTS UNDER NEW ZEALAND-AUSTRALIA 
REGULATORY AGENCY 
 
REF: (A) 05 WELLINGTON 119; (B) 04 WELLINGTON 596 
 
1. (SBU) Begin summary:  Proposed rules for a new Australian-New 
Zealand regulatory agency for therapeutic products will make it 
costlier for U.S. makers of medical devices and complementary 
medicines to operate in New Zealand, according to the manufacturers' 
representatives.  They contend the proposed rules, issued May 23, 
would drive many of their products out of New Zealand.  In contrast, 
the pharmaceutical industry expects the agency would expedite the 
process for obtaining marketing approval for medicines and would 
save the industry in regulatory costs.  Its support of the agency, 
however, hinges on the New Zealand government continuing to allow 
direct-to-consumer advertising of prescription drugs, which is not 
allowed in Australia.  Meanwhile, the government does not yet have 
enough political support to pass the legislation necessary to set up 
the agency.  End summary. 
 
2. (U) Australia and New Zealand signed an agreement in December 
2003 to provide unified regulation of prescription pharmaceuticals 
as well as therapeutic goods that have been virtually unregulated in 
New Zealand, including medical devices, over-the-counter medicines, 
dietary and nutritional supplements, and cosmetics and toiletries 
(ref B).  The proposed agency -- the Australia New Zealand 
Therapeutic Products Authority -- would replace the Australian 
Therapeutic Goods Administration (TGA) and the New Zealand Medicines 
and Medical Devices Safety Authority (Medsafe).  The deadline for 
public submissions on the draft rules is August 15.  The New Zealand 
government is hoping to introduce legislation in July to establish 
the agency and open the agency's doors in the second half of 2007. 
 
3. (SBU) The agency's opening has been delayed a number of times 
previously (ref A), and passage of the implementing legislation is 
far from certain.  The Labour-led New 
Zealand government lacks the votes in Parliament to pass the 
legislation on its own and has no support yet from any other party. 
Some opponents are concerned about Australia's possible dominance of 
the agency, and others are worried that it would mean higher costs 
for industry and consumers in New Zealand.  Proponents say that New 
Zealand's participation in the joint agency would cost less than if 
it tried on its own to extend its regulatory authority to devices 
and other non-drug health products. 
 
Medical devices, complementary medicines 
---------------------------------------- 
4. (SBU) Under the proposed rules, the agency would require licenses 
for all therapeutic goods and recover all its regulatory costs 
through fees and charges.  That would be particularly burdensome for 
New Zealand's medical device and complementary medicine sectors, 
which have not been required to obtain pre-market approval for their 
products and pay no licensing or other regulatory fees.  While the 
draft rules provide for a three-year transition period for product 
licenses to be obtained, industry representatives expect the fees to 
be so high that they will have to seek cheaper sources -- outside 
the United States -- for medical devices and complementary 
medicines.  They expect the fees to be similar to those already 
charged in Australia, which has a population and market roughly five 
times as large as New Zealand's.  They predict the compliance costs 
would force many smaller distributors and importers out of business 
in New Zealand. 
 
5. (SBU) The draft rules also provide that the agency would conduct 
all conformity assessments for medical devices, including audits of 
manufacturers and testing of products to ensure they meet relevant 
standards, which also would increase the sector's costs.  Medical 
device representatives noted that the proposed agency would accept 
European certification, but not U.S. Food and Drug Administration 
certification.  As one representative said, that points to the need 
for a mutual recognition agreement between Australia and the United 
States, which presumably would enable the joint agency to accept FDA 
certification. 
 
6. (SBU) The industry representatives said they support the agency 
in principle, recognizing the need for regulation of their products 
to ensure public safety.  However, they were disappointed that their 
years of consultations with the government about their concerns 
regarding a new regulatory regime were not reflected in the 
proposal.  They had hoped that the government at least would set 
fees according to the size of the product's market. 
 
Prescription drugs 
------------------ 
7. (SBU) On the other hand, the pharmaceutical industry sees the 
 
WELLINGTON 00000475  002 OF 002 
 
 
joint agency as an improvement over New Zealand's existing small and 
overtaxed regulatory regime, in which obtaining marketing approval 
for prescription medicines can take more than three years.  The 
agency also could represent a cost-savings by providing a single 
point of entry for both markets, as opposed to requiring a product 
license in each country.  The industry is concerned, however, about 
whether labeling rules and other such requirements could be met 
within three years.  It is advocating a five-year transition period. 
 
 
8. (SBU) The drug industry also says it will withdraw support of the 
agency if the New Zealand government uses it as an excuse to ban 
direct-to-consumer advertising (DTCA), which some firms have 
employed to boost sales of unsubsidized medicines in New Zealand's 
tightly restricted market.  Australia allows only disease-based, 
awareness-building advertising, while New Zealand is the only 
country in the world besides the United States that allows the 
pharmaceutical industry to promote its products directly to the 
public.  (The government is reviewing its policy on 
direct-to-consumer advertising of prescription medicines, in 
preparation for drafting new legislation on the regulation of DTCA. 
Such legislation is necessary because the law that would enable New 
Zealand to participate in the joint agency also would repeal the 
Medicines Act 1981, which allows DTCA.) 
 
Comment 
------- 
9. (SBU) The joint agency's higher regulatory costs could lead to a 
decline in sales of U.S. medical devices and other therapeutic 
products in New Zealand.  Failure to recognize FDA certification 
also would add a discriminatory barrier to U.S. medical devices. 
While the need for improving regulation of therapeutic products in 
New Zealand should be acknowledged, post suggests these concerns be 
raised in the Trade and Investment Framework Agreement talks with 
New Zealand scheduled for July 27. 
 
MCCORMICK